XML 71 R4.htm IDEA: XBRL DOCUMENT v3.25.2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Income Statement [Abstract]        
Revenue $ 70 $ 0 $ 70 $ 0
Operating Expenses:        
Research and development 2,253 2,601 4,856 5,842
General and administrative 2,685 2,922 5,930 6,282
Total operating expenses 4,938 5,523 10,786 12,124
Operating loss (4,868) (5,523) (10,716) (12,124)
Other income (expense):        
Investment income, net 216 493 482 1,082
Other expense, net (7) (14) (111) (201)
Total other income 209 479 371 881
Net loss before benefit from income taxes and noncontrolling interests (4,659) (5,044) (10,345) (11,243)
Benefit from income taxes 0 0 (962) (798)
Net loss (4,659) (5,044) (9,383) (10,445)
Less - net income (loss) attributable to noncontrolling interests 0 0 0 0
Net loss attributable to Lisata Therapeutics, Inc. common stockholders $ (4,659) $ (5,044) $ (9,383) $ (10,445)
Basic and diluted loss per share        
Lisata Therapeutics, Inc. common stockholders- basic (in usd per share) $ (0.54) $ (0.61) $ (1.09) $ (1.26)
Lisata Therapeutics, Inc. common stockholders - diluted (in usd per share) $ (0.54) $ (0.61) $ (1.09) $ (1.26)
Weighted average common shares outstanding        
Basic shares (in shares) 8,605 8,308 8,604 8,301
Diluted shares (in shares) 8,605 8,308 8,604 8,301